Study Evaluating Venlafaxine ER in Recurrent Depression

Wyeth

Status and phase: Completed; Phase 4

Conditions: Depressive Disorder, Major; Recurrence

Treatments: Drug: Venlafaxine ER

Study type: Interventional

Funder types: Industry

Identifiers

NCT00046020

0600B-100469

Details and patient eligibility

About

The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression

Enrollment: 1,096 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Clinical diagnosis for recurrent major depression

Exclusion Criteria

• The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine ER during the current episode of major depression or the patient is treatment-resistant
• Known hypersensitivity to venlafaxine or fluoxetine
• History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder